spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  RNA therapeutics 

 HSMN NewsFeed - 23 Apr 2026
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
Biopharmaceuticals Licensing
 HSMN NewsFeed - 10 Apr 2026
Vivatides Therapeutics Announces Oversubscribed $54 Million Series A Financing to Accelerate Extrahepatic RNA Therapeutics Development
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 Mar 2026
Averna Therapeutics Announces Strategic Leadership Expansion
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Feb 2026
Lilly to Acquire Orna Therapeutics to Advance Cell Therapies
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 9 Dec 2025
Mercury Bio Announces Appointment of Casey Perkins as Vice President of Corporate Strategy & Business Development
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 1 Aug 2025
BioMarin Announces Appointment of Ian T. Clark to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Mar 2025
Orna Therapeutics Appoints Joseph Bolen, Ph.D., as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 27 Jan 2025
Averna Therapeutics, formerly known as Exsilio Therapeutics, Appoints Thomas M. Barnes, Ph.D., as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Nov 2024
I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Oct 2024
Kyverna Therapeutics Appoints Mert Aktar to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Oct 2024
Avidity Biosciences Announces FDA Removed Partial Clinical Hold on Delpacibart Etedesiran (del-desiran/AOC 1001)
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Jul 2024
Alltrna Announces Updates to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Apr 2024
Orna Therapeutics Appoints Frank Neumann, M.D., Ph.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Feb 2024
Avidity Biosciences Receives FDA Rare Pediatric Disease Designation for AOC 1044 for Treatment of Duchenne Muscular Dystrophy in People with Mutations Amenable to Exon 44 Skipping
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Jan 2024
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Progressive Multiple Sclerosis
Regenerative Medicine Neurology FDA
 HSMN NewsFeed - 13 Dec 2023
Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101 in the Treatment of Patients With Refractory Myasthenia Gravis
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Aug 2023
Kyverna Therapeutics Extends Series B Financing Round to $145 Million and Brings in New Investors
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 19 Jun 2023
Sirnaomics Advances STP705 for Squamous Cell Carcinoma In Situ into Late-Stage Clinical Development
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Jul 2022
BridGene Biosciences Announces $38.5 Million Series B Financing to Further Develop Its Next Generation Chemoproteomics Platform and First-in-Class Oncology Drugs
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 7 Apr 2022
Rona Therapeutics Announces Completion of $33 Million Series A Financing to Advance Global Discovery and Development of RNA Therapeutics
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 30 Mar 2022
Omega Therapeutics Strengthens Team With Key Management Appointments To Support Its Growth
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Mar 2022
Orna Therapeutics Bolsters Leadership Team with Key Executive and Board Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Jan 2022
Kyverna Therapeutics Closes $85 Million Series B Financing led by Northpond Ventures
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 20 Jan 2022
BioTheryX Announces Appointment of Sahm Nasseri as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Dec 2021
Orna Therapeutics Expands Leadership Team with Key Executive Hires
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Sep 2021
Cartesian Therapeutics Strengthens Leadership Team With Hire of Miloš Miljković, M.D., as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 15 Sep 2021
Kyverna Therapeutics Appoints Ian Clark as Chairman of the Board and Karen Walker as Chief Technology Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Sep 2021
ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 1 Jul 2021
Sirnaomics Secures $105 Million in Series E Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 15 Jun 2021
Senda Biosciences Strengthens Leadership Team with Key Management Hires
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Mar 2021
Aktis Oncology Announces $72M Series A Financing To Advance Breakthrough Radiopharmaceuticals To Treat Solid Tumors
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 24 Feb 2021
Orna Therapeutics Launches with over $100M Raised to Develop a New Class of Fully Engineered Circular RNA Therapies
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 23 Feb 2021
PYC Therapeutics Expands U.S. Executive Leadership Team with the Appointment of Glenn Noronha, PhD, as Chief Development Officer
Biopharmaceutical Drug Delivery Personnel
 HSMN NewsFeed - 9 Nov 2020
DTx Pharma Announces Appointment of Denise Bevers as Chief Operating Officer
Biopharmaceutical Drug Delivery Personnel
 HSMN NewsFeed - 12 Feb 2020
Avidity Biosciences Appoints Joseph Baroldi as Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jan 2020
Kyverna Therapeutics Secures $25 Million Series A Funding from Key Investors and Enters into Strategic Collaboration with Gilead Sciences
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 8 Jan 2019
Cygnal Therapeutics Appoints Pearl S. Huang as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Aug 2018
Oncorus(R), Inc., Names Industry Veteran Ted Ashburn as new President and CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 May 2018
Roivant Expands Senior Leadership with Key Hires
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Apr 2018
Bridge Medicines Appoints Louis M. Renzetti, Ph.D., As Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Feb 2018
ImmunoMet Appoints Vincent J. O'Neill, M.D., B.Sc., M.R.C.P, as Chief Medical Officer, and Allan L. Shaw as Chief Financial Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 16 Jan 2018
RXi Pharmaceuticals Announces Business Strategy to Focus on Immuno-Oncology Programs to Accelerate Growth
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Jul 2017
Medicenna Bolsters Management Team
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 11 Jul 2017
Evelo Biosciences Announces $50 Million Series B Financing and Expansion of Board and Leadership Team
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 13 Jun 2017
Regulus Promotes Mark Deeg, M.D. PhD to Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Jun 2017
Regulus Announces Pipeline Updates and Advancements
Biopharmaceuticals
 HSMN NewsFeed - 13 Apr 2017
Arbutus Injunction Survives Attempted Appeal by Acuitas
Biopharmaceuticals Litigation
 HSMN NewsFeed - 6 Feb 2017
Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development
Biopharmaceutical Oncology Personnel
 HSMN NewsFeed - 28 Sep 2016
Assembly Biosciences Announces Key Additions to Microbiome Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Jun 2016
Regulus Secures $30 Million Growth Capital Credit Facility
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 5 May 2016
Investigational Gene-Based Therapy for Alpha-1 Antitrypsin (AAT) Deficiency Demonstrates Durable Response at Five Years
Biopharmaceuticals
 HSMN NewsFeed - 9 Feb 2016
PhaseRx Strengthens Board of Directors and Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Jan 2016
Akcea Therapeutics Appoints Louis St. L. O'Dea as Chief Medical Officer
Biopharmaceuticals Cardiology Personnel
 HSMN NewsFeed - 15 Dec 2015
Dr. Elizabeth Nabel Joins Moderna Therapeutics’ Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Dec 2015
Flagship Ventures Launches Rubius To Develop Red-Cell Therapeutics(TM)
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 19 Nov 2015
Calimmune Expands Board of Directors, Names R. Scott Greer as Chairman
Biopharmaceuticals HIV/AIDS Personnel
 HSMN NewsFeed - 17 Nov 2015
ARCH Venture Partners, Flagship Ventures and MD Anderson Collaborate to Launch Codiak BioSciences
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 4 Nov 2015
Flagship Ventures Launches Evelo Therapeutics To Develop Microbiome Therapies for Cancer
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 27 Oct 2015
Mirna Therapeutics Appoints Dr. Miguel Barbosa as Executive Vice President and Chief Scientific Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 25 Aug 2015
Regulus Appoints Michael Huang, M.D. as Vice President, Clinical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jun 2015
Alnylam Appoints David-Alexandre Gros, M.D., Senior Vice President, Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Mar 2015
Moderna Appoints Tal Zaks, Former Head of Sanofi Global Oncology, as Chief Medical Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 6 Jan 2015
Isis Pharmaceuticals Appoints Paula Soteropoulos As President And Chief Executive Officer Of Akcea Therapeutics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Jul 2014
Alnylam Elects Amy Schulman to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jun 2014
Lakewood-Amedex Raises $5.5 Million In Series C Preferred Stock Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 16 Jun 2014
Regulus Appoints Paul C. Grint, M.D. as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Mar 2014
Mirna Therapeutics Appoints Casi DeYoung as Chief Business Officer
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 13 Feb 2014
Regulus Appoints Head of Regulus microMarkers(TM) R&D Division
Biopharmaceuticlas Personnel
 HSMN NewsFeed - 6 Feb 2014
Ultragenyx Appoints Clay Siegall, Ph.D. and Matthew Fust to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Feb 2014
Regulus Strengthens Executive Management Team with Addition of David Szekeres as Chief Business Officer and General Counsel
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jan 2014
Alnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as Genetic Medicines
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Jan 2014
Marina Biotech and Mirna Therapeutics Amend License Agreement for the Development of microRNA-Based Therapeutics
Biopharmaceuticals Oncology Licensing
 HSMN NewsFeed - 21 Nov 2013
Syros Pharmaceuticals Appoints Stéphane Bancel to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 Nov 2013
Moderna Therapeutics Announces New Equity Financing, Raising $110M to Develop messenger RNA Therapeutics(TM)
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 17 Oct 2013
Auspex Appoints Pratik Shah as CEO and Expands Executive Team
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 14 Oct 2013
Gregory L. Weaver Joins Atossa Genetics' Board of Directors
Diagnostics Personnel
 HSMN NewsFeed - 31 Jul 2013
Biotech Industry Veteran Joseph Bolen Joins Moderna Therapeutics to be President of Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 May 2013
Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Apr 2013
Henri A. Termeer Joins Moderna Therapeutics Board Of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 Jan 2013
Mirna Therapeutics Inc. Appoints Clay B. Siegall, Ph.D., to Its Board of Directors
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Dec 2012
Sirnaomics Advances Its Novel siRNA Therapeutics Against HPV Infection and Cervical Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 27 Nov 2012
Regulus Appoints Victor Knopov, Ph.D. as Vice President, Pharmaceutical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Oct 2012
Mirna Therapeutics Secures $34.5 Million Series C Financing to Advance Oncology microRNA Pipeline into the Clinic
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 27 Jun 2012
Alnylam Expands and Develops Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Oct 2011
Arrowhead Research Appoints Bruce Given M.D. Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 Aug 2011
Mirna Therapeutics Announces Completion of Financing Round
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 28 Jul 2011
Genzyme and Isis Announce Submission of European Marketing Authorization Application for Mipomersen (Kynamro(R))
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 29 Jun 2011
Alnylam Files Answer and Counterclaim Related to Tekmira Lawsuit
Biopharmaceuticals Litigation
 HSMN NewsFeed - 13 Jun 2011
Alnylam Appoints Akshay Vaishnaw as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 May 2011
Regulus Therapeutics Expands Executive Team with Recent Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Mar 2011
Regulus Therapeutics Appoints Lars Karlsson, M.D., Ph.D., VP of Immunology and Fibrosis
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2011
Regulus Therapeutics Promotes Garry E. Menzel, Ph.D., to Chief Operating Officer and Executive Vice President of Finance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Dec 2010
Alnylam Elects Marsha Fanucci to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Dec 2010
Regulus Therapeutics Strengthens Immunology Leadership Team with New Key Appointment
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Oct 2010
Sanofi-Aventis Completes $10 Million Equity Investment in Regulus Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 21 Oct 2010
Dicerna Pharmaceuticals Announces Second Close of Series B Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 11 Aug 2010
Dicerna Closes $25 Million Series B Financing
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 6 May 2010
Dicerna Names Douglas Fambrough as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Apr 2010
Mirina Corporation Closes Series A-1 Financing Led by Versant Ventures
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 11 Jan 2010
Regulus Therapeutics Appoints Zachary A. Zimmerman, Ph.D., Director of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jan 2010
Alnylam Provides Key Goals and Guidance for Next 12 to 18 Months
Biopharmaceuticals
 HSMN NewsFeed - 5 Jan 2010
Intuity Medical Closes $64 Million Series D Financing - One of the Largest Medical Device Funding Events of 2009
Devices Monitoring Endocrinology Venture Capital
 HSMN NewsFeed - 16 Dec 2009
Silence Therapeutics to Merge with Intradigm Corp to Create Leading RNAi Therapeutics Company
Biopharmaceuticals Mergers & Acquisitions Personnel
 HSMN NewsFeed - 12 Nov 2009
Mirna Therapeutics Appoints Dr. Paul Lammers as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 20 May 2009
Genzyme and Isis Announce that Mipomersen Phase 3 Study in Patients with Homozygous Familial Hypercholesterolemia Met Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 19 Feb 2009
Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Jan 2009
Alnylam and Collaborators at Harvard Medical School Demonstrate In Vivo Silencing of Key Genes Implicated in the Transmission of Herpes Simplex Virus-2 (HSV-2)
Biopharmaceuticals
 HSMN NewsFeed - 20 Jan 2009
Alnylam Provides Update on Kreutzer-Limmer Patent Family
Biopharmaceuticals
 HSMN NewsFeed - 3 Dec 2008
AVI BioPharma Files IND for Clinical Trial of Marburg Virus Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Dec 2008
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 25 Nov 2008
Awarepoint Corporation Closes $13.3 M Series D Financing Round
Devices Venture Capital
 HSMN NewsFeed - 7 Oct 2008
Odyssey Thera Announces New Equity Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 1 Oct 2008
Alnylam Appoints Industry Leader John Schmidt as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Sep 2008
Regulus Therapeutics Appoints Dr. Stelios Papadopoulos to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Aug 2008
Regulus Therapeutics Appoints Garry Menzel, Ph.D., as Executive Vice President Corporate Development and Finance
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jul 2008
Isis Announces Appointment of Martin P. Bedigian, M.D. as Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jul 2008
Abbott Invests Additional $20M in Isis' Subsidiary Ibis Biosciences
Biopharmaceuticals
 HSMN NewsFeed - 24 Jun 2008
Genzyme and Isis Complete Licensing of Mipomersen
Biopharmaceuticals Licensing
 HSMN NewsFeed - 10 Jun 2008
Nastech Initiates New Corporate Direction with Name Change to MDRNA, Inc. and Appointment of J. Michael French as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 May 2008
Alnylam and Takeda Form Strategic Worldwide Platform Alliance in RNAi Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2008
Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit
Biopharmaceuticals Personnel
 HSMN NewsFeed - 25 Apr 2008
FDA Provides Clarity to Isis Regarding the Development Path for Mipomersen
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Apr 2008
Asuragen Launches Mirna Therapeutics
Diagnostics Biopharmaceuticals
 HSMN NewsFeed - 30 Mar 2008
Tekmira Pharmaceuticals and Protiva Biotherapeutics Announce Business Combination to Create Global Leader in RNAi Delivery and Therapeutics
Biopharmaceuticals
 HSMN NewsFeed - 11 Feb 2008
Regulus Therapeutics Appoints Peter S. Linsley, Ph.D. as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Jan 2008
Isis Announces Equity Investment in Ibis Biosciences Subsidiary by Abbott; Option Acquired to Purchase Remaining Ibis Equity
Biopharmaceuticals Diagnostics Acquisitions
 HSMN NewsFeed - 7 Jan 2008
Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
Biopharmaceuticals Cardiology Licensing
 HSMN NewsFeed - 14 Dec 2007
Isis Announces Appointment of B. Lynne Parshall as Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Dec 2007
Regulus Therapeutics Appoints Kleanthis G. Xanthopoulos, Ph.D. as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Oct 2007
Isis Adds New Drug to Its Development Pipeline: ISIS 388626 Targeting SGLT2 for the Treatment of Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 10 Oct 2007
New Leaf Venture Partners Closes $450 Million Healthcare Fund
Venture Capital
 HSMN NewsFeed - 8 Oct 2007
Anaptys Biosciences Appoints R. Scott Greer to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Sep 2007
Oxford Bioscience Partners Promotes Dr. Douglas Fambrough to General Partner
Venture Capital Personnel
 HSMN NewsFeed - 2 May 2007
AVI BioPharma and Ercole Biotech Announce License and Drug Development Agreement for Duchenne Muscular Dystrophy and Beta Thalassemia
Biopharmaceuticals
 HSMN NewsFeed - 9 Apr 2007
Innovative Pulmonary and PEGylation-Based Therapeutic Product Development Drives Business Strategy of Nektar Therapeutics
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Mar 2007
CytRx RNAi Subsidiary, RXi Pharmaceuticals, Names Vice President of Pharmaceutical Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jan 2007
Nektar Appoints Howard W. Robin President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Dec 2006
Merck & Co., Inc. Announces Completion of Acquisition of Sirna Therapeutics, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 28 Dec 2006
Sirna Therapeutics Shareholders Approve Acquisition by Merck & Co.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 27 Dec 2006
Protiva Dismisses, Without Prejudice, Its California Litigation Against Inex
Biopharmaceuticals Litigation
 HSMN NewsFeed - 14 Dec 2006
Merck & Co. and Sirna Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period for the Proposed Acquisition of Sirna by Merck
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 12 Dec 2006
Merck Remains Confident in Future Growth as it Executes on New Strategy
Biopharmaceuticals
 HSMN NewsFeed - 30 Oct 2006
Merck & Co., Inc. to Acquire Sirna Therapeutics, Inc.
Biopharmaceuticals Oncology Mergers & Acquisitions
 HSMN NewsFeed - 8 Sep 2006
Protiva Files Suit Against Inex in California Superior Court
Biopharmaceuticals Litigation
Return to NewsFeed  

 Additional items found! 30

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 30 additional stories matching:
RNA therapeutics
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!